Pacira ( (PCRX) ) has released its Q4 earnings. Here is a breakdown of the information Pacira presented to its investors.
Pacira BioSciences, Inc., a leader in non-opioid pain management therapies, operates in the biopharmaceutical sector with a focus on musculoskeletal pain solutions. The company recently reported its financial results for the fourth quarter and full year of 2024, highlighting record revenues of $701 million despite a GAAP net loss of $100 million. The adjusted EBITDA for the year stood at $224 million.
Pacira’s financial performance in 2024 was marked by a 4% increase in total revenues compared to 2023, driven by growth in product sales such as EXPAREL, ZILRETTA, and iovera°. The company also initiated a share repurchase program and completed a strategic acquisition of GQ Bio Therapeutics to bolster its 5×30 growth strategy. Additionally, Pacira strengthened its leadership team and received FDA clearance for a new iovera° SmartTip for managing chronic low back pain.
Key financial metrics for the fourth quarter of 2024 include revenues of $187.3 million, a GAAP net income of $16 million, and an adjusted EBITDA of $62.5 million. Despite increased operating expenses, Pacira managed to achieve a 3% revenue growth in the fourth quarter compared to the same period in 2023. The company also reported a goodwill impairment of $163.2 million for the year.
Looking ahead, Pacira’s management remains optimistic about its growth prospects, with 2025 financial guidance projecting total revenues between $725 million and $765 million. The company aims to continue expanding its market presence and advancing its innovative pipeline, including the development of PCRX-201, to sustain long-term growth.